Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.

doi:10.1186/s12885-023-10857-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.

BMC cancer - 26 Apr 2023

Lau David K, Fong Caroline, Arouri Faten, Cortez Lillian, Katifi Hannah, Gonzalez-Exposito Reyes, Razzaq Muhammad Bilal, Li Su, Macklin-Doherty Aislinn, Hernandez Monica Arenas, Hubank Michael, Fribbens Charlotte, Watkins David, Rao Sheela, Chau Ian, Cunningham David, Starling Naureen

Abstract excerpt

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended. We conducted a retrospective study to evaluate the impact of implementing DPYD variant testing for patients with gastrointestinal cancers in routine clinical practice in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Capecitabine

Share to Colorectal Cancer Treatments and Studies

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Gastrointestinal Neoplasms

Share to Genotype

Share to Pharmacogenetics

Source

Open in PubMed Open full text

Identifiers

PMID: 37101114
DOI: 10.1186/s12885-023-10857-8
PMCID: PMC10131438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.PMID 37101114Read ↗

Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.Semantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in GreeceSemantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.Semantic proximity Read ↗

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse eventsSemantic proximity Read ↗

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.